The first mechanical heart valve prosthesis designed by Dr Charles Hufnagel was implanted to the descending aorta of a 30 year old woman with severe aortic regurgitation in 1952 1 . Eight years after the initial succesful prosthetic valve implantation, Dr Harken sutured a prosthetic valve (Starr Edwards Valve) to the aortic anulus after removing the diseased native valve.
During the ensuing years different types of valves made from pyrolytic carbon were tried.
Though successfully remedied the aortic valve disease, mechanical prosthesis required lifelong anticoagulation resulting in high rates of bleeding and thrombosis complications.
In the 1960s valves with leafelets that were made from animal tissue were developed as an alternative without an anticoagulation requirement. Indeed, they were superior to mecahanical prosthesis in that regard but they did not last nearly as long. In randomized trials of bioprosthetic or mechanical valves which started enrollment in 1970s, primary valve failure and reoperation rates were higher in patients recieving bioprosthetic valves especially in patients less than 65 years of age [2] [3] [4] . Since these initial reports, several important advancements have been made in design and tissue processing to improve valve hemodynamics and durability. With these improvements, the age cutoff to use bioprosthetic valves was gradually lowered to avoid lifelong anticoagulation. Large studies with prospectively collected data and long term follow-up
are not yet available to determine the clinical impact of such a trend 5 .
Until recently reoperation was the only choice for symptomatic patients with degenerated aortic bioprosthesis. Advanced age and multiple comorbidities put some patients at a higher risk
for a repeat open heart surgery and for many this risk is so prohibitive that there is no other treatment option [6] [7] [8] [9] . Advancements in transcatheter aortic valve replacement (TAVR) and the first successful reported case of VIV (valve in valve) in 2007 10 , brought a new hope for these patients.
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There was no core laboratory. Nevertheless, this comprehensive look provides valuable insights to the transcatheter VIV replacement.
Since this initial experience does not have a control group, the relative risk and efficacy compared to conventional surgical approach remains undefined. However, this series provides some benchmarks when transcatheter VIV therapy is considered for bioprosthetic valve failure.
The 30-day rates of mortality (8.4%%) and stroke (2%%) are not much different from what was observed in the early experience of TAVR for inoperable patients. On the other hand, 3 issues were more frequent and consequential than for TAVR for native AS, including high transvalvular gradients, coronary occlusions and valve malpositioning.
High Transvalvular Gradients
Overall 28% of patents had a mean transvalvular gradient of >20 mmHg. following TAVR. In patients with small surgical prosthesis (internal diameter <20 mm) this rate was doubled. High gradients were also more common when the Edwards valve was used. These findings represent less than ideal hemodynamic results.
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Coronary occlusion
The data in the registry highlight another critical procedural problem and point to the importance of careful patient selection and procedure planning. Coronary artery occlusion with attendant 57% mortality occurred more frequently in the stentless valves and valves with leaflet mounted on the outside of the frames (Figure 1) . It is not clear whether or not there is an "interaction" between the diseased prosthesis and the type of TAVR used although there was no difference in the frequency of the coronary occlusion between the 2 types of transcatheter valve. To prevent this frequently lethal complication, we need to examine the relationships between the coronary artery ostia, the bioprosthetic valve sewing ring, the leaflets, the sinotubular junction and Sinuses of Valsalva. For the time being we should either avoid or use extreme caution in using VIV technique in the particular prosthesis mentioned above that leaves little space between the prosthetic leaflets and coronary ostia.
Malpositioned valve
The malpositioning rate of 15.3% and the need for a second TAVR valve in 8.4% of patients are surprisingly high. The valve that moves cranially during deployment up the aorta can often be managed via catheter techniques. But, if it moves in toward the left ventricle open-heart surgery may be neccessary. These complications can potentially be prevented by clear understanding of 57% mortality occurred more frequently in the stentless valves and valves with le le eaf af fle le l t t t mo mo moun un unte ted d on the outside of the frames (Figure 1) . It is not clear whether or not there is an "interaction" be etw tw wee ee een n th th the e e d d dise eas as ased e prosthesis and the type of T T TAV AVR used altho oug u u h h th th the er ere was no difference in h h he fr frequency of of of th h he c cor oron on onar ar ary y y oc occl cl lus us usio io on n betw w we e een th the e 2 2 ty ty type pe es of of t t tra ans nsca ca ath het eter er er v v val alve ve ve. To To T p p pre reve ve ven nt h his is is f f fre re requ qu quen en ntl tl tly y le le eth h hal al c c com om mpl p ic ic cat at tio io ion, n, n, w we e e ne ne need ed ed to o o ex ex exam am min n ne th th the e e re re ela la l t ti tion on nsh sh s i ip ips s be be etw tw twee ee e n n n th th the c co coro ro r na na ary y y artery ostia, , th th he e e bi bi iop op opro ro ost st the e eti ti tic c c va a alv lv lve e se s s wi wi w ng ng ng r r rin in ng, g, g, th th the e le leaf af afle le lets ts ts, , th th he e e si s no no notu tu tubu bu bula la lar r r ju ju unc nc ncti ti t on on on and Sinuse es the anatomy of different valves, pre-procedural planning with CT scan and use of guiding intraprocedural radioscopic software for positioning 13 .
Long-term outcome
There appears to be no loss of improved valve function in a small number of patients who had 1-year echocardiograms. Follow up is too short and very limited to draw comfort for durability of the VIV technique. The longer term follow up from larger TAVR cohorts cannot be readily used for VIV procedures. For the time being, the impact of the frequently constrained conditions of the functioning VIV, interaction between 2 different prosthetic surfaces on the durability of the transcatheter valve is not clear.
Bioprosthesis now, TAVR later?
The question at hand is: does TAVR offer a reasonable solution to the difficult problem of the severely symptomatic patient with malfunctioning aortic prosthesis who is not a surgical candidate or at very high risk for surgical mortality and morbidity. The answer is a qualified "yes"; not all surgical prostheses are suitable and much improvement in technology and procedural technique is needed.
The question for future is: Should we take the option of VIV-TAVR technique into consideration when deciding the surgical valve type for aortic valve disease patients of all ages?
The answer is a cautious "maybe". In the future, availability of newer interations of TAVR devices specifically for VIV will make this approach more feasible as long as the durability issue is addressed. But the size of the surgically implanted valve will continue to be the most important determinant of the success of the VIV procedure. Accordingly, surgeons who envision a prospective TAVR procedure if a valve bioprosthesis fails should make sure a large valve is implanted during the first surgery 16 . This may require wider use of the root enlargement
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